이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ImpediMed 관리

관리 기준 확인 0/4

ImpediMed's CEO는 Parmjot Bains, Jan2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 A$ 1.60K 가치에 해당하는 회사 주식의 0.001% 직접 소유합니다. 1.60K. 경영진과 이사회의 평균 재임 기간은 각각 0.6 년과 0.7 년입니다.

주요 정보

Parmjot Bains

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.001%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

CEO

Parmjot Bains

less than a year

테뉴어

Dr. Parmjot Bains, M.D. serves as Managing Director at ImpediMed Limited from January 08, 2023 and serves as its Interim CEO and Director from 2024 and served as its Chief Executive Officer since and until...

리더십 팀

이름	위치	테뉴어	보상	소유권
Parmjot Bains	MD, Interim CEO & Director	less than a year	데이터 없음	0.0011% A$ 1.5k
McGregor Grant	Interim Chief Financial & Operating Officer and Executive Director	less than a year	데이터 없음	0.10% A$ 145.9k
Dennis Schlaht	Senior Vice President of R&D and Technology	no data	AU$704.20k	데이터 없음
Tim Benkovic	Senior Vice President of Sales & Customer Success	less than a year	데이터 없음	데이터 없음
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	less than a year	데이터 없음	0.020% A$ 28.4k
Steven Chen	Chief Medical Center	less than a year	데이터 없음	데이터 없음
Leanne Ralph	Company Secretary	9.5yrs	데이터 없음	데이터 없음
Walton Taylor	Medical Director	14.3yrs	데이터 없음	데이터 없음

0.7yrs

평균 재임 기간

경험이 풍부한 관리: IPD 의 관리팀은 경험 (평균 재직 기간 0.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Parmjot Bains	MD, Interim CEO & Director	less than a year	데이터 없음	0.0011% A$ 1.5k
McGregor Grant	Interim Chief Financial & Operating Officer and Executive Director	less than a year	데이터 없음	0.10% A$ 145.9k
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	less than a year	데이터 없음	0.020% A$ 28.4k
Christine Emmanuel-Donnelly	Independent Non-Executive Chair	less than a year	데이터 없음	0.019% A$ 27.7k
Janelle Delaney	Independent Non-Executive Director	less than a year	데이터 없음	0.19% A$ 279.0k
Fiona Bones	Non-Executive Director	less than a year	데이터 없음	0.0040% A$ 5.7k

0.8yrs

평균 재임 기간

경험이 풍부한 이사회: IPD 의 이사회는 경험(평균 재직 기간 0.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

ImpediMed 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

Independent Non-Executive Director recently bought AU$50k worth of stock

Independent Non-Executive Director recently bought AU$100k worth of stock

Independent Non-Executive Director recently bought AU$90k worth of stock

High number of new and inexperienced directors

Independent Non-Executive Director recently bought AU$135k worth of stock

Recent updates

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up